Halozyme Therapeutics Inc
$ 103.12
20.24%
07 Aug - close price
- Market Cap 12,231,373,000 USD
- Current Price $ 103.12
- High / Low $ 103.30 / 90.00
- Stock P/E 30.24
- Book Value 1.85
- EPS 3.41
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.26 %
- ROE 1.74 %
- 52 Week High 103.30
- 52 Week Low 61.23
About
Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company is headquartered in San Diego, California.
Analyst Target Price
$88.22
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-08-06 | 2026-05-11 | 2026-02-17 | 2025-11-03 | 2025-08-05 | 2025-05-06 | 2025-02-18 | 2024-10-31 | 2024-08-06 | 2024-05-07 | 2024-02-20 | 2023-11-06 |
| Reported EPS | 2.17 | 1.2212 | -0.24 | 1.72 | 1.54 | 1.11 | 1.26 | 1.27 | 0.91 | 0.79 | 0.82 | 0.75 |
| Estimated EPS | 1.73 | 1.76 | 2.2 | 1.63 | 1.27 | 0.95 | 1.1588 | 0.98 | 0.76 | 0.7 | 0.83 | 0.71 |
| Surprise | 0.44 | -0.5388 | -2.44 | 0.09 | 0.27 | 0.16 | 0.1012 | 0.29 | 0.15 | 0.09 | -0.01 | 0.04 |
| Surprise Percentage | 25.4335% | -30.6136% | -110.9091% | 5.5215% | 21.2598% | 16.8421% | 8.7332% | 29.5918% | 19.7368% | 12.8571% | -1.2048% | 5.6338% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: HALO
2026-08-09 13:40:58
Halozyme Therapeutics reported record second-quarter results with revenue up to US$481 million and net income of US$229.91 million, leading to increased full-year 2026 revenue guidance. The company also accelerated share buybacks and secured new ENHANZE collaborations, reinforcing its royalty-led business model. While these achievements support the near-term investment narrative, key risks such as partner concentration, reimbursement pressures, and intellectual property challenges persist.
2026-08-09 00:40:52
Halozyme Therapeutics reported strong second-quarter results, with revenue rising to US$481 million and net income to US$229.91 million. The company also increased its full-year 2026 revenue guidance to a range of US$1.84 billion to US$1.91 billion and accelerated share repurchases, completing US$750 million under a 2024 authorization and an additional US$175.01 million under a new 2026 program. These actions, combined with five new ENHANZE collaboration deals, reinforce the company's investment narrative centered on its royalty model, despite ongoing legal and patent challenges.
2026-08-08 19:40:58
Halozyme Therapeutics (HALO) has seen a 106.2% return over five years, but its current valuation suggests the stock is expensive, trading at 29.2x earnings compared to a fair P/E of 20.1x. Despite strong financial results and collaboration agreements, the company's P/E ratio is above the biotech industry average. The analysis concludes that the stock appears overvalued based on current fundamentals and that future returns depend on the company justifying its premium with strong margins and earnings.
2026-08-08 17:19:00
Halozyme Therapeutics reported record second-quarter results with revenue at US$481 million and net income at US$229.91 million, leading to a 24.9% stock increase. The company raised its 2026 revenue guidance to US$1.84 billion - US$1.91 billion and boosted share buybacks by an additional US$175.01 million under a new 2026 program, after completing US$750 million from 2024. This positive outlook is driven by its ENHANZE royalty engine, though legal and patent challenges remain a key risk for investors.
2026-08-08 16:40:58
Analysts have raised the average 12-month price target for Halozyme Therapeutics, Inc. (HALO) stock to $99.56, up from $86.89. This new target suggests a potential upside of approximately 16% from its recent closing price. The consensus rating among 11 analysts remains a "Buy," with 9 analysts recommending a Buy and 2 recommending a Hold.
2026-08-08 14:40:52
Halozyme Therapeutics (HALO) stock rallied 20% after reporting strong Q2 2026 earnings, exceeding revenue and EPS expectations, driven by a 47.5% increase in total revenue and 39.2% increase in net income. The company also raised its full-year 2026 revenue and earnings guidance, reinforcing its "compounding platform" bull case despite ongoing bear concerns about concentration and long-term patent durability.
